GSK Signs Deal With Epix For GPCR Candidates

Epix will be eligible to earn milestones of $1.2 billion based on development and commercialization of four programs, including a Phase II Alzheimer’s molecule.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet